Provided by Tiger Trade Technology Pte. Ltd.

Vallon Pharmaceuticals, Inc.

0.4000
0.0000
Volume:- -
Turnover:- -
Market Cap:10.69M
PE:-0.02
High:0.4000
Open:0.4000
Low:0.4000
Close:0.4000
52wk High:43.95
52wk Low:0.4000
Shares:26.73M
Float Shares:285.77K
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-20.7747
EPS(LYR):-20.7747
ROE:-172.16%
ROA:-69.35%
PB:4.57
PE(LYR):-0.02

Loading ...

Company Profile

Company Name:
Vallon Pharmaceuticals, Inc.
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
As of April 21, 2023, Vallon Pharmaceuticals, Inc. was acquired by GRI Bio, Inc., in a reverse merger transaction. Vallon Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel medications for central nervous system disorders with a focus on abuse-deterrent medications. The company's lead investigational product candidate is ADAIR (Abuse-Deterrent Amphetamine Immediate-Release), an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. It is also developing ADMIR, an abuse deterrent formulation of methylphenidate for the treatment of ADHD. The company was incorporated in 2018 and is based in Philadelphia, Pennsylvania.